Literature DB >> 24132602

Clinical and diagnostic developments of a gamma interferon release assay for use in bovine tuberculosis control programs.

K E Bass1, B J Nonnecke, M V Palmer, T C Thacker, R Hardegger, B Schroeder, A J Raeber, W R Waters.   

Abstract

Currently, the Bovigam assay is used as an official supplemental test within bovine tuberculosis control programs. The objectives of the present study were to evaluate two Mycobacterium bovis-specific peptide cocktails and purified protein derivatives (PPDs) from two sources, liquid and lyophilized antigen preparations. PPDs and peptide cocktails were also used for comparison of a second-generation gamma interferon (IFN-γ) release assay kit with the currently licensed first-generation kit (Bovigam; Prionics AG). Three strains of M. bovis were used for experimental challenge: M. bovis 95-1315, M. bovis Ravenel, and M. bovis 10-7428. Additionally, samples from a tuberculosis-affected herd (i.e., naturally infected) were evaluated. Robust responses to both peptide cocktails, HP (PC-HP) and ESAT-6/CFP10 (PC-EC), and the PPDs were elicited as early as 3 weeks after challenge. Only minor differences in responses to Commonwealth Serum Laboratories (CSL) and Lelystad PPDs were detected with samples from experimentally infected animals. For instance, responses to Lelystad M. avium-derived PPD (PPDa) exceeded the respective responses to the CSL PPDa in M. bovis Ravenel-infected and control animals. However, a 1:4 dilution of stimulated plasma demonstrated greater separation of PPDb from PPDa responses (i.e., PPDb minus PPDa) with the use of Lelystad PPDs, suggesting that Lelystad PPDs provide greater diagnostic sensitivity than CSL PPDs. The responses to lyophilized and liquid antigen preparations did not differ. Responses detected with first- and second-generation IFN-γ release assay kits (Bovigam) did not differ throughout the study. In conclusion, antigens may be stored in a lyophilized state without loss in potency, PC-HP and PC-EC are dependable biomarkers for aiding in the detection of bovine tuberculosis, and second-generation Bovigam kits are comparable to currently used kits.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24132602      PMCID: PMC3889511          DOI: 10.1128/CVI.00519-13

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  28 in total

1.  Use of synthetic peptides derived from the antigens ESAT-6 and CFP-10 for differential diagnosis of bovine tuberculosis in cattle.

Authors:  H M Vordermeier; A Whelan; P J Cockle; L Farrant; N Palmer; R G Hewinson
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

2.  Aerosol delivery of virulent Mycobacterium bovis to cattle.

Authors:  M V Palmer; W Ray Waters; D L Whipple
Journal:  Tuberculosis (Edinb)       Date:  2002       Impact factor: 3.131

Review 3.  DIVA reagents for bovine tuberculosis vaccines in cattle.

Authors:  Martin Vordermeier; Gareth J Jones; Adam O Whelan
Journal:  Expert Rev Vaccines       Date:  2011-07       Impact factor: 5.217

4.  Mycobacterium bovis antigens for the differential diagnosis of vaccinated and infected cattle.

Authors:  Martin Vordermeier; Stephen V Gordon; R Glyn Hewinson
Journal:  Vet Microbiol       Date:  2011-02-24       Impact factor: 3.293

5.  Optimizing antigen cocktails for detection of Mycobacterium bovis in herds with different prevalences of bovine tuberculosis: ESAT6-CFP10 mixture shows optimal sensitivity and specificity.

Authors:  C Aagaard; M Govaerts; V Meikle; A J Vallecillo; J A Gutierrez-Pabello; F Suarez-Güemes; J McNair; A Cataldi; C Espitia; P Andersen; J M Pollock
Journal:  J Clin Microbiol       Date:  2006-09-27       Impact factor: 5.948

6.  Tuberculin manufacturing source and breakdown incidence rate of bovine tuberculosis in British cattle, 2005-2009.

Authors:  S H Downs; R S Clifton-Hadley; P A Upton; I C Milne; E R Ely; R Gopal; A V Goodchild; A R Sayers
Journal:  Vet Rec       Date:  2012-11-16       Impact factor: 2.695

7.  Optimization of a whole-blood gamma interferon assay for detection of Mycobacterium bovis-infected cattle.

Authors:  Irene Schiller; W Ray Waters; H Martin Vordermeier; Brian Nonnecke; Michael Welsh; Nicolas Keck; Adam Whelan; Teresa Sigafoose; Christoph Stamm; Mitchell Palmer; Tyler Thacker; Roland Hardegger; Beatrice Marg-Haufe; Alex Raeber; Bruno Oesch
Journal:  Clin Vaccine Immunol       Date:  2009-07-01

8.  Efficacy and immunogenicity of Mycobacterium bovis DeltaRD1 against aerosol M. bovis infection in neonatal calves.

Authors:  W Ray Waters; Mitchell V Palmer; Brian J Nonnecke; Tyler C Thacker; Charles F Capinos Scherer; D Mark Estes; R Glyn Hewinson; H Martin Vordermeier; S Whitney Barnes; Glenn C Federe; John R Walker; Richard J Glynne; Tsungda Hsu; Brian Weinrick; Karolin Biermann; Michelle H Larsen; William R Jacobs
Journal:  Vaccine       Date:  2009-01-09       Impact factor: 3.641

9.  Perspectives on the History of Bovine TB and the Role of Tuberculin in Bovine TB Eradication.

Authors:  Margaret Good; Anthony Duignan
Journal:  Vet Med Int       Date:  2011-04-17

10.  Comparison of the MGIT 960, BACTEC 460 TB and solid media for isolation of Mycobacterium bovis in United States veterinary specimens.

Authors:  Suelee Robbe-Austerman; Doris M Bravo; Beth Harris
Journal:  BMC Vet Res       Date:  2013-04-11       Impact factor: 2.741

View more
  8 in total

1.  IP-10 Is a Sensitive Biomarker of Antigen Recognition in Whole-Blood Stimulation Assays Used for the Diagnosis of Mycobacterium bovis Infection in African Buffaloes (Syncerus caffer).

Authors:  Wynand J Goosen; David Cooper; Michele A Miller; Paul D van Helden; Sven D C Parsons
Journal:  Clin Vaccine Immunol       Date:  2015-06-24

2.  Interleukin-17A as a Biomarker for Bovine Tuberculosis.

Authors:  W Ray Waters; Mayara F Maggioli; Mitchell V Palmer; Tyler C Thacker; Jodi L McGill; H Martin Vordermeier; Linda Berney-Meyer; William R Jacobs; Michelle H Larsen
Journal:  Clin Vaccine Immunol       Date:  2015-12-16

3.  Characterization of effector and memory T cell subsets in the immune response to bovine tuberculosis in cattle.

Authors:  Mayara F Maggioli; Mitchell V Palmer; Tyler C Thacker; H Martin Vordermeier; W Ray Waters
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

4.  Antigen-Specific IP-10 Release Is a Sensitive Biomarker of Mycobacterium bovis Infection in Cattle.

Authors:  Sven D C Parsons; Kevina McGill; Mairead B Doyle; Wynand J Goosen; Paul D van Helden; Eamonn Gormley
Journal:  PLoS One       Date:  2016-05-11       Impact factor: 3.240

5.  Use of fecal volatile organic compound analysis to discriminate between non-vaccinated and BCG-Vaccinated cattle prior to and after Mycobacterium bovis challenge.

Authors:  Christine K Ellis; Somchai Rice; Devin Maurer; Randal Stahl; W Ray Waters; Mitchell V Palmer; Pauline Nol; Jack C Rhyan; Kurt C VerCauteren; Jacek A Koziel
Journal:  PLoS One       Date:  2017-07-07       Impact factor: 3.240

6.  Development and evaluation of a diagnostic cytokine-release assay for Mycobacterium suricattae infection in meerkats (Suricata suricatta).

Authors:  Charlene Clarke; Stuart James Patterson; Julian Ashley Drewe; Paul David van Helden; Michele Ann Miller; Sven David Charles Parsons
Journal:  BMC Vet Res       Date:  2017-01-04       Impact factor: 2.741

7.  Bovine Tuberculosis Antemortem Diagnostic Test Agreement and Disagreement in a Naturally Infected African Cattle Population.

Authors:  Robert F Kelly; Lina Gonzaléz Gordon; Nkongho F Egbe; Emily J Freeman; Stella Mazeri; Victor N Ngwa; Vincent Tanya; Melissa Sander; Lucy Ndip; Adrian Muwonge; Kenton L Morgan; Ian G Handel; Barend M de C Bronsvoort
Journal:  Front Vet Sci       Date:  2022-07-07

8.  A pilot study exploring the use of breath analysis to differentiate healthy cattle from cattle experimentally infected with Mycobacterium bovis.

Authors:  Christine K Ellis; Randal S Stahl; Pauline Nol; W Ray Waters; Mitchell V Palmer; Jack C Rhyan; Kurt C VerCauteren; Matthew McCollum; M D Salman
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.